Chiltern Announces Agreement to Acquire Theorem Clinical Research
News Aug 13, 2015
Chiltern has announced that it has signed a purchase agreement to acquire Theorem Clinical Research, another leading global CRO.
“This is a direct response to client demand for a clinical research partner that can provide scientific and operating strengths globally, in a responsive and flexible way,” said Dr. Jim Esinhart, Chiltern CEO. “This transaction will bring together more than 3,700 people in more than 45 countries dedicated to the philosophy of “Designed Around You.”
“Chiltern and Theorem have carved out complementary niches, even across key geographies,” said Dr. John Potthoff, Theorem president and CEO. “In key areas, our capabilities will dovetail into current Chiltern operations — this is a mutually beneficial deal.”
The combined company will operate under the name Chiltern and will gain global reach - most notably in China and Japan - as well as new service offerings for medical devices and diagnostics, clinical analytics and clinical supplies.
The planned transaction between the two organizations is subject to customary regulatory and closing conditions. Both companies will follow antitrust guidelines and continue to function as separate and independent entities until the acquisition is approved. The transaction is expected to close within the next several weeks.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Key to Creating Better Medicines with Less Side EffectsNews
A new study published in Science by Professors Yossi Paltiel of the Hebrew University of Jerusalem and Ron Naaman from the Weizmann Institute of Science describes a breakthrough technology with the power to create drugs with fewer unwanted side effects.
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018